OREANDA-NEWS. January 29, 2013. GE Capital, Healthcare Financial Services announced today it is serving as sole lender and administrative agent on USD 12 million in senior secured credit facilities for SIGA Technologies, Inc. (NASDAQ: SIGA), consisting of a USD 5 million term loan and a USD 7 million revolving line of credit.

Headquartered in New York City, SIGA specializes in the development and commercialization of pharmaceuticals to prevent and treat some of the most lethal, disease-causing pathogens in the world, including smallpox, Ebola, dengue, Lassa fever and other dangerous viruses.

“GE Capital understands our business and quickly delivered a competitive financing package that meets our needs,” said Daniel Luckshire, executive vice president and CFO of SIGA. “In GE Capital, we have a lender who will work closely with us as we continue to grow our business.”

“SIGA, like many commercial-stage pharmaceutical companies, has sophisticated needs for continuing access to efficiently-priced capital,” said Anthony Storino, senior managing director, GE Capital, Healthcare Financial Services, Life Sciences. “With a team of specialists, we provide pharma companies with a deep level of knowledge and great flexibility in meeting their capital needs.”